RPL17 and neoplasm: The combination therapy resulted in a more significant reduction in tumor size and growth compared to the control group (P < 0.001), Anti-PD-1 alone (P < 0.05), and arsenic sulfide alone (P < 0.001) (Figure 6B, Supplementary Figure S4B).